Ladies and gentlemen, welcome to the Cognizant Technology Solutions’ Fourth Quarter 2024 Earnings Conference Call. All lines ...

Ravi Singisetti; Chief Executive Officer, Director; Cognizant Technology Solutions Corp Jatin Dalal; Chief Financial Officer; Cognizant Technology Solutions Corp Thank you, operator, and good ...

A combination of homegrown capabilities and significant acquisitions has made Cognizant a key player in bringing AI to ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

Ladies and gentlemen, welcome to the Cognizant Technology Solutions' Fourth Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the ...

Cognizant Technology Solutions CTSH is scheduled to report its fourth-quarter 2024 results on Feb. 05. The Zacks Consensus ...

and user acceptanc Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even ...

Pre-earnings options volume in Cognizant (CTSH) is 2.8x normal with puts leading calls 9:8. Implied volatility suggests the market is ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Fourth quarter revenue of $5.1 billion increased 6.8% year-over-year or 6.7% in constant currency1, at the high end of our guidance rangeFull-year revenue of $19.7 billion increased 2.0% ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...